Select a State

Global health R&D delivers for Louisiana

US government investment in global health R&D has delivered

$86.8 million
to Louisiana research institutions
1,200+ new jobs
for Louisiana

Neglected diseases in Louisiana

Chikungunya cases
24
Dengue cases
32
HIV diagnoses
10,216
Malaria cases
73
Tuberculosis cases
1,442
West Nile cases
685
Zika cases
39

Louisiana's top USG-funded global health R&D institutions

Tulane University of Louisiana
$61.6 million
Louisiana State University and A&M College (including Health Sciences Center New Orleans)
$20.1 million
National Hansen's Disease Program
$4.9 million
Loyola University New Orleans
$215 thousand
Southern University at Shreveport
$9 thousand

Louisiana industry in global health R&D

Autoimmune Technologies:
Location(s):
New Orleans
BASF Corporation
Location(s):
Geismar
Bioceptive
Location(s):
New Orleans
Novate Medical Technologies
Location(s):
New Orleans

Louisiana's top areas of global health R&D by USG funding

28.0%
HIV/AIDS
13.7%
Malaria
28.7%
Tuberculosis
3.7%
Diarrheal diseases
5.3%
Ebola/viral hemorrhagic fevers
13.7%
Neglected tropical diseases
Dengue
Kinetoplastids
Leprosy
5.7%
Other
Non-allocable
Salmonella infections

Global health R&D at work in Louisiana

Researchers from Tulane University and Louisiana State University have helped discover a possible explanation for the rapid spread of Ebola. The team found that a compound known as the “delta peptide” is produced in large amounts in Ebola patients. The investigators theorize that it may be a specific type of viral protein that damages host cells by making their membranes become permeable; in the case of Ebola, this contributes to severe vomiting, internal bleeding, and extreme gastrointestinal distress in patients—in turn contributing to the virus’ spread. The discovery could lead to new treatments for this deadly and highly contagious disease.

Footnotes